Kinase-independent role of mTOR and on-/off-target effects of an mTOR kinase inhibitor.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

1. Integrative Strategies to Enhance Enzyme-Protein Interactions for Drug Discovery and Biocatalysis.Applied biochemistry and biotechnology · 2026
   Article
2. Metabolic reprogramming in T cell senescence: a novel strategy for cancer immunotherapy.Cell death discovery · 2025
   Review
3. Metal-organic framework-based smart stimuli-responsive drug delivery systems for cancer therapy: advances, challenges, and future perspectives.Journal of nanobiotechnology · 2025
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

12 authors at 2 institutions in 2 countries.

Funding

Abstract

Indexed as